Innova Therapeutics Accelerates Cancer Treatment Innovation with Enci Acquisition

Advancements in Cancer Treatment

Innova Therapeutics, a biopharmaceutical company based in Charleston, South Carolina, has announced a significant step forward in cancer treatment through the acquisition of Enci Therapeutics. This strategic move is poised to enhance Innova's flagship program, IVT-8086, an innovative monoclonal antibody that specifically targets SFRP2, a protein associated with various solid and hematological tumors.

What is IVT-8086?

IVT-8086 is a first-in-class humanized monoclonal antibody designed to antagonize the Secreted Frizzled-Related Protein 2 (SFRP2). SFRP2 plays a critical role in several signaling pathways involved in cancer progression, including the Wnt/Calcium (Ca2+) pathway. By inhibiting this pathway, IVT-8086 has demonstrated powerful anti-tumor effects in preclinical models, significantly reducing tumor burden in both primary and metastatic tumors.

In addition to its direct effects on tumor cells, IVT-8086 also influences various components of the tumor microenvironment, including endothelial cells, T cells, and tumor-associated macrophages (TAMs). This multifaceted approach enables IVT-8086 to target not only the tumor but also the supportive cells that contribute to tumor growth and metastasis.

The Merger Details

As part of the acquisition, Innova Therapeutics has absorbed Enci's research and development capabilities, particularly its advanced therapeutic strategies employing IVT-8086. While specific financial details of the transaction remain undisclosed, the acquisition reinforces Innova's commitment to developing effective cancer therapies.

Dr. Robert Ryan, CEO of Innova, expressed that this acquisition marks a pivotal moment for the company in line with its mission to deliver innovative and life-saving treatments. He stated that